Document Detail


Clinical implications of midventricular obstruction and intravenous propranolol use in transient left ventricular apical ballooning (Tako-tsubo cardiomyopathy).
MedLine Citation:
PMID:  18294491     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Persistent hypotension with dynamic midventricular obstruction (MVO) in patients with transient left ventricular (LV) apical ballooning (Tako-tsubo cardiomyopathy) is an important complication that needs to be treated. PURPOSE: The objective of this study is to determine the effects of intravenous propranolol challenge on MVO in transient LV apical ballooning. SUBJECTS AND METHODS: Thirty-four patients (12 males, 22 females, mean age 64 +/- 17 years, age range 22-84 years) with LV apical ballooning were enrolled. The hemodynamic and echocardiographic effects of propranolol (0.05 mg/kg, maximum 4 mg) were analyzed in 13 patients. RESULTS: (1) Midventricular obstruction was present in 8 (24%) of 34 patients, and the pressure gradient (PG) ranged from 28 to 140 mm Hg. (2) Patients with MVO had similar demographic and clinical characteristics (symptoms, peak creatine kinase, plasma catecholamine levels) as those without MVO; however, in patients with MVO, abnormal Q waves on electrocardiogram and hypotension were more prevalent. (3) In the MVO group, intravenous propranolol changed the PG from 90 +/- 42 to 22 +/- 9 mm Hg, the systolic blood pressure (SBP) from 85 +/- 11 to 116 +/- 20 mm Hg, and the LV ejection fraction (LVEF) from 30% +/- 7% to 43% +/- 4%. (4) In all subjects, the changes in the PG after propranolol injection had a significant linear correlation with the SBP and LVEF changes: deltaSBP = 4.738 + 0.315 x deltaPG (r = 0.689 (P < .001) and deltaLVEF = 2.973 + 0.1321 x deltaPG (r = 0.715, P < .001). CONCLUSION: Intravenous propranolol is useful for treating dynamic MVO in patients with transient LV apical ballooning.
Authors:
Takuji Yoshioka; Akiyoshi Hashimoto; Kazufumi Tsuchihashi; Kazuhiko Nagao; Michifumi Kyuma; Hitoshi Ooiwa; Akihiko Nozawa; Shinya Shimoshige; Mariko Eguchi; Takeru Wakabayashi; Satoshi Yuda; Mamoru Hase; Tomoaki Nakata; Kazuaki Shimamoto
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-01-18
Journal Detail:
Title:  American heart journal     Volume:  155     ISSN:  1097-6744     ISO Abbreviation:  Am. Heart J.     Publication Date:  2008 Mar 
Date Detail:
Created Date:  2008-02-25     Completed Date:  2008-03-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0370465     Medline TA:  Am Heart J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  526.e1-7     Citation Subset:  AIM; IM    
Affiliation:
Second Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / administration & dosage*
Adult
Aged
Aged, 80 and over
Blood Pressure
Dose-Response Relationship, Drug
Echocardiography / methods
Female
Follow-Up Studies
Humans
Injections, Intravenous
Male
Middle Aged
Propranolol / administration & dosage*
Stroke Volume / physiology
Takotsubo Cardiomyopathy / complications*,  drug therapy,  physiopathology
Ventricular Outflow Obstruction / drug therapy*,  etiology,  physiopathology
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 525-66-6/Propranolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic impli...
Next Document:  Associations between neurohormonal and inflammatory activation and heart failure in children.